Previous 10 | Next 10 |
2024-03-12 20:26:02 ET Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Presentation ...
NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / We're committed to increasing diverse representation in clinical trials, especially for those who have been historically underrepresented. Our 2024 Toward Health Equity Oncology Grant focuses on inclusion in trials and supports the mission of 36 g...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024. On February 2...
2024-03-10 08:39:57 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-03-08 13:46:51 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for ...
2024-03-08 11:48:18 ET Summary Thirty-nine companies, including Coca-Cola and Telephone and Data Systems, are raising their dividends. Strong dividend-growth outperforms slow or no dividend-growth. The article provides tables and metrics to help investors make informed decisio...
2024-03-08 07:50:18 ET More on Dividends SCHD and the dividend ETF landscape -- SA analysts weigh in 3 Dividend Growth Stocks To Buy In March 2024 Why Dividend Investors Should Be Smiling 4 Factor Dividend Growth Portfolio - Firing On All Cylinders My...
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead Sciences For many people living with cancer, hearing about the experiences of others can be helpful. Dale, who is living with breast cancer, shares her journey and point of view about how sharing information can help reduce health disparitie...
– New Data Evaluating the Efficacy and Safety Profile of Biktarvy for the Treatment of People with HIV and Hepatitis B or Tuberculosis will be Presented – – Retrospective Analysis Evaluating HIV Resistance-Associated Mutations Reinforces Importance of Treatm...
2024-03-06 12:54:39 ET More on Gilead Sciences, Merck Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript) Gilead's Business Development: ...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...